A study has found that young adults with diabetes have high rates of cardiometabolic risk factors such as adiposity, blood pressure, chronic kidney disease, and history of cardiovascular disease. These risk factors can lead to an increased disease prevalence and mortality rate among these young adults as they age.
The National Association of Specialty Pharmacy's annual meeting is one of the industry’s only conferences where all stakeholders can fully participate.
NAMI Basics OnDemand is an adaptation of the in-person NAMI Basics, a free, 6-session education program for parents, caregivers, and other family who provide care for adolescents aged 22 years or younger who are experiencing mental health symptoms.
TIN Rx is aiming to serve the most vulnerable populations, including LGBTQ patients, homeless patients, and others who may typically face stigma in pharmacies.
Brolucizumab is the most clinically advanced humanized single-chain antibody fragment. This type of antibody is highly sought after due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics.
Top news of the day from across the health care landscape.
Trifarotene is the only topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin. The cream is also the first topical treatment specifically studied and proven to treat both facial (forehead, cheeks, nose, and chin) and truncal (chest, shoulders, and back).
Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.
The new drug application for PF708 was submitted under the 505(b)(2) regulatory pathway with teriparatide injection as the reference drug.
The keynote, Priming Pharmacists for Making an Impact in Oncology Value-Based Care, sets the stage for the entire conference and highlights how pharmacists are critical to the multidisciplinary team in providing value in patient-centered oncology care.
Ron Lanton III, Esq., discusses the Prescription Drug Price Relief Act of 2019 at the National Association of Specialty Pharmacists Annual Meeting at Washington, DC.
Top news of the day from across the health care landscape.
The study aimed to determine the association between antidepressant classes, types, and duration of use during pregnancy and the risk of gestational diabetes.
A new study by Prime Therapeutics LLC has shown a sharp increase in the number of drug "super spenders," defined by the researchers as members with pharmacy and medical drug therapy claims of $250,000 or more annually.
Ixekizumab showed superiority versus guselkumab in the treatment of moderate to severe plaque psoriasis.
Subcutaneous immunoglobin has increased treatment options for patients with several conditions, such as primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy.
A first-in-human trial evaluating the safety, pharmacokinetics, and fecal microbiome effects of a novel DNA polIIIC inhibitor demonstrated the antibacterial’s promise as a potential treatment alternative to vancomycin for the treatment of Clostridioides difficile.
Benralizumab is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid depletion of eosinophils via programmed cell death.
The PARP inhibitor received a Breakthrough Therapy Designation for metastatic castration-resistant prostate cancer based on data released from the GALAHAD study.
Top news of the day from across the health care landscape.
The FDA has awarded a cooperative agreement grant to the National Association of Boards of Pharmacy to develop a 3-year pilot project for a data-sharing system to improve oversight of compounding pharmacies.
Top news of the day from across the health care landscape.
Two cell mutations have been linked to acute myeloid leukemia, but the reason for their cooperation has been unknown.
Just as vaccinations get under way in full force, a few indicators raise the question about whether the vaccine really is as well matched as was anticipated.
The funding is awarded to health departments representing 57 geographic areas to expand treatment and prevention efforts for HIV/AIDS.
The newly published guidelines answer 16 core questions about the diagnosis and treatment of CAP in adults. The guidelines are more narrow in scope than previous versions and focus primarily on the care of a patient with active pneumonia.
The black-white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades.
The FDA has approved emtricitabine 200 mg and tenofovir alafenamide 25 mg (Descovy, Gilead Sciences Inc.) as a second pre-exposure prophylaxis drug in at-risk adults and adolescents weighing at least 75 Ib.
Study offers a new perspective on the molecular events that may lead some individuals to develop multiple sclerosis.
Top news of the day from across the health care landscape.
